Major Depressive Disorder Resources

Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Also called major depressive disorder or clinical depression, it affects how you feel, think and behave and can lead to a variety of emotional and physical problems. You may have trouble doing normal day-to-day activities, and sometimes you may feel as if life isn't worth living.

More than just a bout of the blues, depression isn't a weakness and you can't simply "snap out" of it. Depression may require long-term treatment. But don't get discouraged. Most people with depression feel better with medication, psychotherapy or both.¹

Journal of Managed Care + Specialty Pharmacy

• Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder.  Journal of Managed Care + Specialty Pharmacy, 2021 Feb;27(2):223-239.
• Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.  Journal of Managed Care + Specialty Pharmacy, 2018 Aug;24(8):726-734.
• Economic burden and antidepressant treatment patterns among patients with major depressive disorder in the United States. Journal of Managed Care + Specialty Pharmacy, 2022 Nov;28(11-a Suppl):S2-S13.

Additional Publications

• Antidepressants and health-related quality of life (HRQoL) for patients with depression: Analysis of the medical expenditure panel survey from the United States. Almohammed O A, Alsalem A A, Almangour A A, et al. PLoS One. 2022, Apr. doi: 10.1371/journal.pone.0265928.
• Prevalence of Depression Symptoms in US Adults Before and During the COVID-19 Pandemic. Ettman C K, Abdalla S M, Cohen G H. JAMA Netw Open. 2020, Sep. doi:10.1001/jamanetworkopen.2020.19686.
• The Increasing Economic Burden with Additional Steps of Pharmacotherapy in Major Depressive Disorder. Arnaud A, Suthoff E, Tavares R M, et al. Pharmacoeconomics. 2021, Jun. doi: 10.1007/s40273-021-01021-w.
• The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018). Greenberg P E, Fournier A, Sisitsky T, et al.  Pharmacoeconomics. 2021, Jun. doi: 10.1007/s40273-021-01019-4.
• Treatment-resistant major depressive disorder: Canadian expert consensus on definition and assessment. Rybak Y E, Lai K S P, Ramasubbu R, et al. Depress Anxiety. 2021, Apr. doi: 10.1002/da.23135.
• Prospective biomarkers of major depressive disorder: a systematic review and meta-analysis. Kennis M, Gerritsen L, van Dalen M, et al. Mol Psychiatry. 2020, Feb. doi: 10.1038/s41380-019-0585-z.
• Neuroimaging Biomarkers for Predicting Treatment Response and Recurrence of Major Depressive Disorder. Kang S, Cho S. Int J Mol Sci. 2020, Mar. doi: 10.3390/ijms21062148.
• Glial mechanisms underlying major depressive disorder: Potential therapeutic opportunities. Rahman S, Alzarea S. Prog Mol Biol Transl Sci. 2019. doi: 10.1016/bs.pmbts.2019.06.010.
• C-Reactive Protein as a Biomarker for Major Depressive Disorder? Orsolini L, Pompili S, Tempia Valenta S, et al. Int J Mol Sci. 2022, Jan. doi: 10.3390/ijms23031616.
• Sequential Combination of Pharmacotherapy and Psychotherapy in Major Depressive Disorder: A Systematic Review and Meta-analysis. Guidi J, Fava G A. JAMA Psychiatry. 2021, Mar. doi: 10.1001/jamapsychiatry.2020.3650.

Sponsored by Sage Therapeutics.

_{1. MayoClinic. (n.d.) Depression (major depressive disorder). Retrieved from https://www.mayoclinic.org/diseases-conditions/depression/symptoms-causes/syc-20356007.}